Cholesterol care | New York
Repatha is the brand name for evolocumab, a PCSK9 inhibitor given by subcutaneous injection. Its current U.S. label includes cardiovascular risk reduction in adults at increased risk, LDL lowering in adults with hypercholesterolemia, and certain patients age 10 years and older with familial hypercholesterolemia. Patients or caregivers generally inject Repatha after appropriate training; it is not an in-clinic-only medicine.
Repatha has an active U.S. marketing listing. The current DailyMed labeling reviewed for this page was updated in January 2026 and reflects prescribing information revised in August 2025. This page describes evaluation and care coordination. A prescription, coverage, dispensing, teaching visit, or administration is never automatic.
The current label covers reduction of major adverse cardiovascular events in adults at increased risk and LDL reduction in adults with hypercholesterolemia. It also covers patients age 10 years and older with heterozygous or homozygous familial hypercholesterolemia.
The clinician should clarify the exact indication, LDL level and goal, cardiovascular and family history, and prior treatment response. The review also covers adherence, age, allergies, pregnancy or lactation considerations, and the patient's ability to use and store an injectable medicine.
Adults commonly use 140 mg every two weeks or 420 mg monthly under the label. The patient or caregiver should receive training and follow the instructions for the prescribed device and regimen.
The plan should include lipid follow-up and review of injection-site reactions, hypersensitivity, adherence, storage, technique, and treatment response. The full label governs use in children and in familial hypercholesterolemia.
A brand name is not enough to determine whether treatment is appropriate. The clinician must connect the label to the patient's diagnoses, current medicines, prior treatment, laboratory results, preferences, and coverage.
The clinician should clarify the exact indication, LDL level and goal, cardiovascular and family history, and prior treatment response. The review also covers adherence, age, allergies, pregnancy or lactation considerations, and the patient's ability to use and store an injectable medicine.
The plan should include lipid follow-up and review of injection-site reactions, hypersensitivity, adherence, storage, technique, and treatment response. The full label governs use in children and in familial hypercholesterolemia.
Confirm prescribing, prior authorization, dispensing, cold-chain counseling, device teaching, and follow-up. Do not build an in-clinic administration workflow by default.
Repatha is not interchangeable with every PCSK9 product. Device, dose, schedule, labeled population, coverage criteria, and patient preference differ. A clinic card does not mean that Repatha is stocked or administered there.
An evaluation may lead to another medicine, more testing, a referral, or no medication change.
The health plan and dispensing pharmacy make coverage and fulfillment decisions. Prior authorization may be required.
The clinic cards below show places to start an evaluation. They do not prove that a product is stocked, dispensed, taught, or administered at that site.
The sequence protects safety and keeps a product request from bypassing diagnosis, records, monitoring, access, or referral needs.
Bring recent lipid results, a current medication and supplement list, prior reactions, relevant diagnoses, and family history when available.
The clinician reviews the reason for treatment, prior response, safety considerations, adherence barriers, and the role of lifestyle support.
The plan may include repeat or additional testing, a medication change, teaching, prior-authorization work, specialist coordination, or continued monitoring.
The care team confirms how results and symptoms will be reviewed. Product supply or administration is arranged only after operational capability is verified.
Choose a nearby Nao Medical clinic as a starting point for evaluation or care coordination.
Capability boundary: these location cards do not establish that a medicine, device, laboratory test, injection, or specialty workflow is available at every site. Confirm the exact service before travel.
Bronx
932 E 174th St, Bronx, NY 10460
A place to begin evaluation and care coordination near West Farms, Crotona Park East, and nearby Bronx neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Queens
37-15 23rd Ave, Astoria, NY 11105
A place to begin evaluation and care coordination near Astoria, Ditmars, East Elmhurst, and nearby Queens neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Bronx
2063A Bartow Ave, Bronx, NY 10475
A place to begin evaluation and care coordination near Co-op City, Pelham Bay, Baychester, and nearby Bronx neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Brooklyn
341 Eastern Pkwy, Brooklyn, NY 11216
A place to begin evaluation and care coordination near Crown Heights, Prospect Heights, and nearby Brooklyn neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Long Island
232 W Old Country Rd, Hicksville, NY 11801
A place to begin evaluation and care coordination near Hicksville, Plainview, Bethpage, and nearby Nassau County communities. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Queens
80-10 Northern Blvd, Jackson Heights, NY 11372
A place to begin evaluation and care coordination near Jackson Heights, Elmhurst, Corona, and nearby Queens neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Queens
90-18 Sutphin Blvd, Jamaica, NY 11435
A place to begin evaluation and care coordination near Jamaica, Briarwood, Richmond Hill, and nearby Queens neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Queens
30-07 36th Ave, Astoria, NY 11106
A place to begin evaluation and care coordination near Long Island City, Astoria, Sunnyside, and nearby Queens neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Long Island
135 Mineola Blvd, Mineola, NY 11501
A place to begin evaluation and care coordination near Mineola, Garden City, Westbury, and nearby Nassau County communities. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Manhattan
259 1st Ave, New York, NY 10003
A place to begin evaluation and care coordination near StuyTown, the East Village, Gramercy, and nearby Manhattan neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Brooklyn
308 Graham Ave, Brooklyn, NY 11211
A place to begin evaluation and care coordination near Williamsburg, Greenpoint, Bushwick, and nearby Brooklyn neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Use these focused pages to compare options, prepare for an evaluation, and connect medication questions with broader care.
Explore broader cardiovascular prevention and cholesterol care at Nao Medical.
Compare another self-injected PCSK9 antibody without assuming equivalent dosing.
Review a monthly self-injected PCSK9-binding option.
Learn how a healthcare-professional-administered option differs.
Assess inherited high cholesterol and family risk.
Answers reflect the current official sources and the limited evaluation-and-coordination scope described on this page.
These sources support product identity, approval, current labeling, availability, and clinical boundaries. They do not prove Nao Medical site capability or health-plan coverage.
Current indications, dose options, self-injection instructions, age ranges, and safety information.
Open official sourceCurrent risk assessment, LDL-lowering treatment, Lp(a), ApoB, and monitoring guidance.
Open official sourcePatient-selection principles and the roles of Lp(a), ApoB, and nonstatin therapies.
Open official sourceSource and label check completed August 1, 2026. Named clinical and operations review is still pending.
General information only. This page is not medical advice and does not replace diagnosis, treatment, or guidance from a licensed clinician.
Content was updated August 1, 2026 from the sources cited on this page. Medical guidance, prescribing information, medication availability, and insurance rules can change. A licensed clinician must confirm current information and determine each patient's eligibility, testing, treatment, administration setting, and follow-up. Call 911 for a medical emergency. Contact Nao Medical with a question or correction.
(917) 310-3371